

Philippe Conus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5187414/publications.pdf>

Version: 2024-02-01

193
papers

7,574
citations

61984

43
h-index

64796

79
g-index

221
all docs

221
docs citations

221
times ranked

7928
citing authors

#	ARTICLE	IF	CITATIONS
1	N-Acetyl Cysteine as a Glutathione Precursor for Schizophreniaâ€”A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	1.3	489
2	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.4	321
3	Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16621-16626.	7.1	275
4	A 600â€¦kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. <i>Journal of Medical Genetics</i> , 2012, 49, 660-668.	3.2	251
5	The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. <i>Schizophrenia Bulletin</i> , 2012, 38, 316-330.	4.3	219
6	Setting the stage: from prodrome to treatment resistance in bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 671-678.	1.9	204
7	Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities. <i>JAMA Psychiatry</i> , 2016, 73, 20.	11.0	195
8	Developing Psychosis and Its Risk States Through the Lens of Schizotypy. <i>Schizophrenia Bulletin</i> , 2015, 41, S396-S407.	4.3	191
9	Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. <i>Schizophrenia Research</i> , 2007, 95, 1-8.	2.0	174
10	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. <i>Bipolar Disorders</i> , 2011, 13, 87-98.	1.9	155
11	Transdiagnostic clinical staging in youth mental health: a first international consensus statement. <i>World Psychiatry</i> , 2020, 19, 233-242.	10.4	153
12	Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. <i>Journal of Psychiatric Research</i> , 2008, 42, 982-990.	3.1	140
13	Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. <i>BMC Medicine</i> , 2012, 10, 111.	5.5	130
14	Diagnostic Stability 18 Months After Treatment Initiation for First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1239-1246.	2.2	130
15	Stage managing bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 471-477.	1.9	129
16	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 317-327.	4.3	121
17	Symptomatic and functional outcome 12â€¦months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. <i>Bipolar Disorders</i> , 2006, 8, 221-231.	1.9	110
18	Pretreatment and Outcome Correlates of Sexual and Physical Trauma in an Epidemiological Cohort of First-Episode Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2010, 36, 1105-1114.	4.3	110

#	ARTICLE	IF	CITATIONS
19	Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. <i>Schizophrenia Research</i> , 2010, 118, 256-263.	2.0	107
20	The First-Episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. <i>Microbial Biotechnology</i> , 2007, 1, 191-200.	1.7	100
21	Predictors of Service Disengagement in First-Admitted Adolescents With Psychosis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 990-999.	0.5	95
22	Treatment and Early Intervention in Psychosis Program (TIPP-PLAN): implementation of an early intervention programme for psychosis in Switzerland. <i>Microbial Biotechnology</i> , 2013, 7, 322-328.	1.7	92
23	The proximal prodrome to first episode mania – a new target for early intervention. <i>Bipolar Disorders</i> , 2008, 10, 555-565.	1.9	90
24	First-Episode Mania: A Neglected Priority for Early Intervention. <i>Australian and New Zealand Journal of Psychiatry</i> , 2002, 36, 158-172.	2.3	86
25	Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1185-1196.	4.3	83
26	Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. <i>Bipolar Disorders</i> , 2010, 12, 244-252.	1.9	79
27	The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and Inhibition. <i>Biological Psychiatry</i> , 2016, 80, 129-139.	1.3	78
28	MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. <i>Molecular Psychiatry</i> , 2020, 25, 2889-2904.	7.9	76
29	Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Study Design and Baseline Characteristics. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 818-829.	2.3	74
30	Prevalence and Predictors of Suicide Attempt in an Incidence Cohort of 661 Young People with First-Episode Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 149-157.	2.3	74
31	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.9	71
32	Characterizing the connectome in schizophrenia with diffusion spectrum imaging. <i>Human Brain Mapping</i> , 2015, 36, 354-366.	3.6	70
33	Early intervention in bipolar disorders: opportunities and pitfalls. <i>Medical Journal of Australia</i> , 2007, 187, S11-4.	1.7	68
34	An evidence map of psychosocial interventions for the earliest stages of bipolar disorder. <i>Lancet Psychiatry</i> , 2015, 2, 548-563.	7.4	68
35	From neuroprogression to neuroprotection: implications for clinical care. <i>Medical Journal of Australia</i> , 2010, 193, S36-40.	1.7	68
36	Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1417-e1423.	2.2	67

#	ARTICLE	IF	CITATIONS
37	Characterisation of the prodrome to a first episode of psychotic mania: Results of a retrospective study. <i>Journal of Affective Disorders</i> , 2010, 124, 341-345.	4.1	66
38	Public health significance of bipolar disorder: implications for early intervention and prevention. <i>Bipolar Disorders</i> , 2014, 16, 548-556.	1.9	64
39	Prevalence, Predictors, and Consequences of Long-Term Refusal of Antipsychotic Treatment in First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 565-572.	1.4	63
40	Motivational Intervention to Reduce Cannabis Use in Young People with Psychosis: A Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 287-297.	8.8	56
41	Genetic Dysregulation of Glutathione Synthesis Predicts Alteration of Plasma Thiol Redox Status in Schizophrenia. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2003-2010.	5.4	56
42	Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First Study. <i>Biological Psychiatry</i> , 2018, 84, 253-264.	1.3	56
43	Quetiapine<i>v.</i>lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. <i>British Journal of Psychiatry</i> , 2017, 210, 413-421.	2.8	53
44	Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia. <i>Molecular Psychiatry</i> , 2022, 27, 1886-1897.	7.9	53
45	Cannabis use disorder and age at onset of psychosis “ A study in first-episode patients. <i>Schizophrenia Research</i> , 2011, 129, 52-56.	2.0	46
46	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1259-1272.	3.5	44
47	N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. <i>Translational Psychiatry</i> , 2018, 8, 220.	4.8	44
48	Understanding urbanicity: how interdisciplinary methods help to unravel the effects of the city on mental health. <i>Psychological Medicine</i> , 2021, 51, 1099-1110.	4.5	44
49	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	11.0	44
50	Pharmacotherapy of first-episode psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 717-750.	1.8	43
51	Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics. <i>Microbial Biotechnology</i> , 2007, 1, 49-60.	1.7	42
52	Influence of<i>CRTC1</i>Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population. <i>JAMA Psychiatry</i> , 2013, 70, 1011.	11.0	42
53	Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. <i>Molecular Psychiatry</i> , 2022, 27, 1192-1204.	7.9	40
54	Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis. <i>Journal of Affective Disorders</i> , 2004, 81, 259-268.	4.1	39

#	ARTICLE	IF	CITATIONS
55	Difficult-to-Engage Patients: A Specific Target for Time-Limited Assertive Outreach in a Swiss Setting. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 845-850.	1.9	39
56	Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2014, 40, 973-983.	4.3	39
57	Unpacking "the City": An experience-based approach to the role of urban living in psychosis. <i>Health and Place</i> , 2016, 42, 104-110.	3.3	38
58	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 199-207.	2.3	37
59	Mild Depressive Symptoms Mediate the Impact of Childhood Trauma on Long-Term Functional Outcome in Early Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2017, 43, 1027-1035.	4.3	37
60	Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12495-12500.	7.1	37
61	Age at the Time of Exposure to Trauma Modulates the Psychopathological Profile in Patients With Early Psychosis. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e612-e618.	2.2	37
62	Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. <i>Microbial Biotechnology</i> , 2011, 5, 100-107.	1.7	34
63	Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. <i>Microbial Biotechnology</i> , 2012, 6, 380-388.	1.7	34
64	Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment. <i>Journal of Psychiatric Research</i> , 2016, 77, 15-21.	3.1	34
65	Duration of untreated psychosis: a proposition regarding treatment definition. <i>Microbial Biotechnology</i> , 2011, 5, 301-308.	1.7	33
66	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
67	Readiness to Participate in Psychiatric Research. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 480-484.	1.9	31
68	Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: Pilot study. <i>Schizophrenia Research</i> , 2018, 191, 80-86.	2.0	31
69	Brain connectivity alterations in early psychosis: from clinical to neuroimaging staging. <i>Translational Psychiatry</i> , 2019, 9, 62.	4.8	31
70	Urbanicity: The need for new avenues to explore the link between urban living and psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 398-409.	1.7	31
71	Impulsivity in early psychosis: A complex link with violent behaviour and a target for intervention. <i>European Psychiatry</i> , 2018, 49, 30-36.	0.2	30
72	Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Treatment Adherence. <i>Frontiers in Psychiatry</i> , 2018, 9, 294.	2.6	30

#	ARTICLE	IF	CITATIONS
73	Sensorimotor Induction of Auditory Misattribution in Early Psychosis. <i>Schizophrenia Bulletin</i> , 2020, 46, 947-954.	4.3	28
74	Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. <i>Psychopharmacology</i> , 2018, 235, 13-22.	3.1	27
75	N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 478-487.	2.1	25
76	Pre-morbid and outcome correlates of first episode mania with psychosis: Is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?. <i>Journal of Affective Disorders</i> , 2010, 126, 88-95.	4.1	24
77	Pharmacogenetic Study on Risperidone Long-Acting Injection. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 289-298.	1.4	24
78	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. <i>European Psychiatry</i> , 2015, 30, 975-982.	0.2	24
79	History of offending behavior in first episode psychosis patients: A marker of specific clinical needs and a call for early detection strategies among young offenders. <i>Schizophrenia Research</i> , 2015, 161, 163-168.	2.0	23
80	Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 1089-1099.	3.1	23
81	Emplacing recovery: how persons diagnosed with psychosis handle stress in cities. <i>Psychosis</i> , 2017, 9, 322-329.	0.8	22
82	Violent behaviour in early psychosis patients: Can we identify clinical risk profiles?. <i>Microbial Biotechnology</i> , 2019, 13, 517-524.	1.7	22
83	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
84	High b-value diffusion-weighted imaging: A sensitive method to reveal white matter differences in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 144-151.	1.8	21
85	Timely N-Acetyl-Cysteine and Environmental Enrichment Rescue Oxidative Stress-Induced Parvalbumin Interneuron Impairments via MMP9/RAGE Pathway: A Translational Approach for Early Intervention in Psychosis. <i>Schizophrenia Bulletin</i> , 2021, 47, 1782-1794.	4.3	21
86	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. <i>Frontiers in Psychiatry</i> , 2019, 10, 606.	2.6	20
87	Identifying patterns in psychiatric hospital stays with statistical methods: towards a typology of post-deinstitutionalization hospitalization trajectories. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2019, 54, 1411-1417.	3.1	20
88	Gender differences in first episode psychotic mania. <i>BMC Psychiatry</i> , 2013, 13, 82.	2.6	19
89	Assertive outreach for "difficult to engage" patients: A useful tool for a subgroup of patients in specialized early psychosis intervention programs. <i>Psychiatry Research</i> , 2016, 239, 212-219.	3.3	19
90	Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. <i>Schizophrenia Research</i> , 2017, 185, 130-136.	2.0	19

#	ARTICLE	IF	CITATIONS
91	Stable biomarker identification for predicting schizophrenia in the human connectome. <i>NeuroImage: Clinical</i> , 2020, 27, 102316.	2.7	19
92	Internal and Predictive Validity of the French Health of the Nation Outcome Scales: Need for Future Directions. <i>PLoS ONE</i> , 2016, 11, e0160360.	2.5	18
93	Association of CRTCL1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. <i>Journal of Affective Disorders</i> , 2016, 198, 43-49.	4.1	18
94	Partialâ€volume modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic schizophrenia. <i>Human Brain Mapping</i> , 2020, 41, 4041-4061.	3.6	18
95	A psychoeducation tool for patients with first-episode psychosis. <i>Acta Neuropsychiatrica</i> , 2011, 23, 75-77.	2.1	17
96	Urban remediation: a new recovery-oriented strategy to manage urban stress after first-episode psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 273-283.	3.1	17
97	Sudden death among young people with first-episode psychosis: An 8â€10year follow-up study. <i>Psychiatry Research</i> , 2010, 177, 305-308.	3.3	16
98	Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression. <i>PLoS ONE</i> , 2015, 10, e0139155.	2.5	16
99	Are we missing opportunities for early intervention in bipolar disorder?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 5-7.	2.8	15
100	Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 219-229.	1.5	15
101	Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. <i>Schizophrenia Research</i> , 2012, 140, 31-36.	2.0	14
102	The Swiss Early Psychosis Project SWEPP: a national network. <i>Microbial Biotechnology</i> , 2012, 6, 106-111.	1.7	13
103	Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 258-265.	1.3	13
104	Early intervention for bipolar disorder â€ Do current treatment guidelines provide recommendations for the early stages of the disorder?. <i>Journal of Affective Disorders</i> , 2019, 257, 669-677.	4.1	13
105	Migration in patients with early psychosis: A 3-year prospective follow-up study. <i>Psychiatry Research</i> , 2019, 275, 108-114.	3.3	13
106	The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: Trauma and early psychotic mania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1017-1024.	2.3	12
107	Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 246-258.	1.5	12
108	Trajectory and predictors of quality of life in first episode psychotic mania. <i>Journal of Affective Disorders</i> , 2016, 195, 148-155.	4.1	12

#	ARTICLE	IF	CITATIONS
109	Early onset of cannabis use and violent behavior in psychosis. <i>European Psychiatry</i> , 2020, 63, e78.	0.2	12
110	Redox Dysregulation and Oxidative Stress in Schizophrenia: Nutrigenetics as a Challenge in Psychiatric Disease Prevention. <i>World Review of Nutrition and Dietetics</i> , 2010, 101, 131-153.	0.3	11
111	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 982-983.	3.3	11
112	Change in Emotional and Theory of Mind Processing in Borderline Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 935-943.	1.0	11
113	Fronto-Temporal Disconnection Within the Presence Hallucination Network in Psychotic Patients With Passivity Experiences. <i>Schizophrenia Bulletin</i> , 2021, 47, 1718-1728.	4.3	11
114	Exploring the clinical relevance of a dichotomy between affective and non-affective psychosis: Results from a first-episode psychosis cohort study. <i>Microbial Biotechnology</i> , 2022, 16, 168-177.	1.7	10
115	Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication. <i>PLoS ONE</i> , 2020, 15, e0242569.	2.5	10
116	Clozapine is more efficacious for tongue dystonia than olanzapine. <i>Psychopharmacology</i> , 2002, 162, 89-89.	3.1	9
117	Visuospatial Working Memory Deficits and Visual Pursuit Impairments are Not Directly Related in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 766-774.	2.3	9
118	Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 547-557.	1.5	9
119	Social and academic premorbid adjustment domains predict different functional outcomes among youth with first episode mania. <i>Journal of Affective Disorders</i> , 2017, 219, 133-140.	4.1	9
120	Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531989138.	2.7	9
121	Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. <i>Pharmacopsychiatry</i> , 2021, 54, 279-286.	3.3	9
122	Evidence of mediation of severity of anxiety and depressive symptoms between abuse and positive symptoms of psychosis. <i>Journal of Psychiatric Research</i> , 2022, 150, 353-359.	3.1	9
123	Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 531-541.	2.5	9
124	Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 244-250.	2.4	8
125	Redox Dysregulation and Oxidative Stress in Schizophrenia: Nutrigenetics as a Challenge in Psychiatric Disease Prevention. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2010, 3, 267-289.	1.3	8
126	Beyond clinical staging of psychiatric disorders. <i>Lancet Psychiatry</i> , 2015, 2, e27.	7.4	8

#	ARTICLE	IF	CITATIONS
127	Community Treatment Order: Identifying the need for more evidence based justification of its use in first episode psychosis patients. <i>Schizophrenia Research</i> , 2017, 185, 67-72.	2.0	8
128	Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 464-472.	1.5	8
129	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. <i>Clinical Pharmacokinetics</i> , 2020, 59, 371-382.	3.5	8
130	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , 2021, 11, 360.	4.8	8
131	Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	8
132	Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. <i>Gene</i> , 2017, 628, 8-15.	2.2	7
133	Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. <i>BMC Psychiatry</i> , 2022, 22, 342.	2.6	7
134	Familial Psychopathology in the First Episode Psychosis Outcome Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 617-626.	2.3	6
135	Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. <i>Microbial Biotechnology</i> , 2014, 8, 358-365.	1.7	6
136	The impact of insight in a first-episode mania with psychosis population on outcome at 18 months. <i>Journal of Affective Disorders</i> , 2014, 167, 74-79.	4.1	6
137	The coupling of low-level auditory dysfunction and oxidative stress in psychosis patients. <i>Schizophrenia Research</i> , 2017, 190, 52-59.	2.0	6
138	Moderating role of cannabis use between insight and depression in early psychosis. <i>Schizophrenia Research</i> , 2020, 215, 61-65.	2.0	6
139	A narrative review of intervention in first-episode affective psychoses. <i>Journal of Psychiatric Research</i> , 2021, 143, 123-137.	3.1	6
140	Termination of therapy: what can clinicians do to maximise gains?. <i>Acta Neuropsychiatrica</i> , 2010, 22, 43-45.	2.1	5
141	Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 544-552.	1.4	5
142	Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients. <i>Clinical Epigenetics</i> , 2019, 11, 198.	4.1	5
143	Rate and predictors of disengagement in an early psychosis program with time limited intensification of treatment. <i>Journal of Psychiatric Research</i> , 2020, 131, 33-38.	3.1	5
144	White Matter Alterations Between Brain Network Hubs Underlie Processing Speed Impairment in Patients With Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab033.	1.7	5

#	ARTICLE	IF	CITATIONS
145	Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?. Australian and New Zealand Journal of Psychiatry, 2006, 40, 199-207.	2.3	5
146	Daily Dose Effects of Risperidone on Weight and Other Metabolic Parameters. Journal of Clinical Psychiatry, 2022, 83, .	2.2	5
147	Duration of untreated psychosis: What are we talking about?. Acta Neuropsychiatrica, 2009, 21, 106-108.	2.1	4
148	Patients participating to neurobiological research in early psychosis: A selected subgroup?. Schizophrenia Research, 2018, 201, 249-253.	2.0	4
149	City Avoidance in the Early Phase of Psychosis: A Neglected Domain of Assessment and a Potential Target for Recovery Strategies. Frontiers in Psychiatry, 2019, 10, 342.	2.6	4
150	Topology predicts long-term functional outcome in early psychosis. Molecular Psychiatry, 2020, 26, 5335-5346.	7.9	4
151	Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 509-523.	1.4	3
152	Trauma and psychosis: some aspects of a complex relationship. Acta Neuropsychiatrica, 2009, 21, 148-150.	2.1	3
153	Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenetics and Genomics, 2016, 26, 208-217.	1.5	3
154	Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances. Frontiers in Psychiatry, 2018, 9, 573.	2.6	3
155	“Is “early intervention” in bipolar disorder what it claims to be?” Malhi et Al. Bipolar Disorders, 2018, 20, 181-183.	1.9	3
156	Precision psychiatry: Promises made“Promises to be kept?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 841-843.	2.3	3
157	Mechanisms of change in brief treatments for borderline personality disorder: a protocol of a randomized controlled trial. Trials, 2020, 21, 335.	1.6	3
158	Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 26-35.	2.5	3
159	A protocol for the first episode psychosis outcome study (<sc>FEPOS</sc>): “15% year follow-up after treatment at the <sc>Early Psychosis Prevention and Intervention Centre, Melbourne, Australia</sc>. Microbial Biotechnology, 2022, 16, 715-723.	1.7	3
160	Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2019, 80, .	2.2	3
161	Six months functional response to early psychosis intervention program best predicts outcome after three years. Schizophrenia Research, 2021, 238, 62-69.	2.0	3
162	Encoding dysfunctions in a dynamic“static paradigm for visuospatial working memory in first-episode psychosis patients: a 2-year follow-up study. Microbial Biotechnology, 2009, 3, 44-51.	1.7	2

#	ARTICLE	IF	CITATIONS
163	Subtyping based on premorbid profile: A strategy to personalize treatment in first-episode affective psychosis. <i>Microbial Biotechnology</i> , 2022, 16, 51-60.	1.7	2
164	Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution. <i>Clinical and Translational Science</i> , 2021, 14, 2544-2555.	3.1	2
165	Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort. <i>Frontiers in Psychiatry</i> , 2021, 12, 756403.	2.6	2
166	Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia; Response to Adaptive changes to oxidative stress in schizophrenia by Lena Palaniyappan. <i>Molecular Psychiatry</i> , 2022, 27, 3567-3568.	7.9	2
167	Preventive strategies in bipolar disorders: identifying targets for early intervention. , 0, , 223-240.		1
168	T52. N-ACETYL-CYSTEINE ADD-ON TREATMENT LEADS TO AN IMPROVEMENT OF FORNIX WHITE MATTER INTEGRITY IN EARLY PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S133-S134.	4.3	1
169	Frontal cortical thickness correlates positively with impulsivity in early psychosis male patients. <i>Microbial Biotechnology</i> , 2019, 13, 848-852.	1.7	1
170	Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?. <i>Microbial Biotechnology</i> , 2022, 16, 256-263.	1.7	1
171	Not in education, employment and training status in the early stages of bipolar I disorder with psychotic features. <i>Microbial Biotechnology</i> , 2021, , .	1.7	1
172	Patients'™, carers'™ and clinicians'™ attitudes towards alternative terms to describe the at-risk for psychosis state. <i>Schizophrenia Research</i> , 2021, 237, 69-75.	2.0	1
173	Evolution of impulsivity levels in relation to early cannabis use in violent patients in the early phase of psychosis. <i>Psychological Medicine</i> , 2022, , 1-10.	4.5	1
174	The differential impact of duration of untreated psychosis on functioning and quality of life: A threshold analysis. <i>Microbial Biotechnology</i> , 2023, 17, 354-360.	1.7	1
175	Symptom dimensions stability over time in recent onset psychosis: A prospective study. <i>Schizophrenia Research</i> , 2022, 246, 126-131.	2.0	1
176	PRE-TREATMENT, BASELINE AND TREATMENT CORRELATES OF OUTCOME IN AN EPIDEMIOLOGICAL COHORT OF FIRST EPISODE PSYCHOSIS PATIENTS. <i>Schizophrenia Research</i> , 2010, 117, 282-283.	2.0	0
177	Nonpharmacological Substances for Early Intervention. <i>Key Issues in Mental Health</i> , 0, , 159-167.	0.6	0
178	M3. Topological Analyses of Metabolomic Data to Identify Markers of Early Psychosis and Disease Biotypes. <i>Schizophrenia Bulletin</i> , 2017, 43, S211-S212.	4.3	0
179	SA58. The First-Episode Psychosis Outcome Study: Preliminary Data on the Long-Term Follow-Up of First-Episode Psychosis Patients Who Were Treated at the Early Psychosis Prevention and Intervention Centre Between 1998 and 2000. <i>Schizophrenia Bulletin</i> , 2017, 43, S134-S134.	4.3	0
180	16.2 CHILDHOOD TRAUMA ENGAGES OXIDATIVE STRESS, HIPPOCAMPUS ALTERATIONS, AND POORER CLINICAL OUTCOME IN EARLY PSYCHOSIS PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S25-S26.	4.3	0

#	ARTICLE	IF	CITATIONS
181	Qui a besoin de suivi intensif dans le milieu dans un programme spÃ©cialisÃ© pour les psychoses Ã©mergentes?. Annales Medico-Psychologiques, 2018, 176, 74-79.	0.4	0
182	S164. "AT-RISK MENTAL STATES" PROGRAM IN LAUSANNE: INFLUENCE OF RECRUITMENT STRATEGIES ON THE RATE OF FALSE POSITIVES. Schizophrenia Bulletin, 2018, 44, S389-S389.	4.3	0
183	10.2 REDOX DYSREGULATION, OLIGODENDROCYTES AND WHITE MATTER ALTERATIONS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S15-S16.	4.3	0
184	29.3 TOPOLOGICAL ANALYSIS ENABLES PREDICTION OF FUNCTIONAL AND SOCIAL OUTCOMES IN EARLY PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S137-S137.	4.3	0
185	S69. CLINICAL HIGH RISK STATE: STRATIFICATION BASED ON CLINICAL PROFILE AND REDOX STATUS. Schizophrenia Bulletin, 2020, 46, S60-S60.	4.3	0
186	S143. NEURAL MECHANISMS OF ROBOT-INDUCED HALLUCINATIONS IN HEALTHY PARTICIPANTS AND SYMPTOMATIC HALLUCINATIONS OF NEUROLOGICAL AND PSYCHIATRIC ORIGIN. Schizophrenia Bulletin, 2020, 46, S90-S91.	4.3	0
187	Redox Dysregulation, Myelination Deficit and Dysconnectivity in Schizophrenia: A Translational Study in First Episode Patients and Experimental Models. Biological Psychiatry, 2020, 87, S100.	1.3	0
188	M16. PROFILING GLUTAMATE AND D-SERINE PATHWAYS IN TREATMENT RESISTANT EARLY PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2020, 46, S139-S139.	4.3	0
189	Video ethnography: introducing a new tool from research to psychiatric practice?. Psychosis, 2021, 13, 24-34.	0.8	0
190	DÃ©veloppement de l'insight dans les troubles psychotiques : objectif ou stratÃ©gie thÃ©rapeutique ?. , 2018, , 300-309.		0
191	Recovering the Capacity to Live outside of a Psychiatric Hospital: Impact of a Specialized Inpatient Program. Psychiatric Quarterly, 2021, 92, 751-759.	2.1	0
192	Mapping personal geographies in psychosis: from space to place. Schizophrenia Bulletin Open, 0, , .	1.7	0
193	Grouping affective psychoses in early intervention: Justification for specific treatment guidelines. Psychiatry Research, 2022, 314, 114690.	3.3	0